News Tocagen’s brain tumour candidate gets PRIME designation An early-stage drug candidate for hard-to-treat brain tumours has been granted special ‘PRIME’ status by the European Medicines Agency.
News Immunotherapy for brain cancer gets European PRIME status Latest addition to EMA's fast-track for cutting edge drugs
Articles Europe launches new PRIME fast-track for promising medicines Andrew McConaghie reports on a newly-launched plan to speed up access to groundbreaking new medicines in Europe.
News NHS "isn't delivering equitable care for rare diseases" A Genetic Alliance UK report claims the NHS is failing to meet the needs of many of the 3.5 million people in the country who live with rare diseases.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.